Literature DB >> 35233474

Lung cancer in Europe: The way forward.

Monica Racovita1, Eleanor Wheeler1, Suzanne Wait1, Dani Bancroft1, Rowan Eastabrook1, Tit Albreht2,3, Anne-Marie Baird4,5, Jacek Jassem6, Aoife McNamara7,8, Silvia Novello9,10, Cornel Radu-Loghin11, Jan P van Meerbeeck12,13,14.   

Abstract

Entities:  

Keywords:  COVID-19; Europe; lung cancer; non-communicable diseases; screening; treatment

Year:  2022        PMID: 35233474      PMCID: PMC8845476          DOI: 10.18332/tpc/146645

Source DB:  PubMed          Journal:  Tob Prev Cessat        ISSN: 2459-3087


× No keyword cloud information.
Lung cancer causes more deaths than any other cancer, but for too long, it has not been given the policy attention it deserves. Lung cancer is the main cause of cancer-related deaths in Europe[1], and its burden will remain high for several decades to come. Even though smoking rates are gradually declining[2], people who used to smoke remain at high risk of lung cancer for many years after quitting[3], and environmental factors such as air pollution are a growing cause of lung cancer in the entire population[4]. We have the means to reduce the burden of lung cancer on our society, but it will require a comprehensive and integrated approach. Importantly, we need to dispel the perception that lung cancer is a self-inflicted condition. We could start by treating smoking as an addiction and reducing stigma towards both smoking and lung cancer. Early detection needs to be enhanced by implementing largescale screening programmes that target high-risk individuals, alongside smoking cessation programmes. The evidence is clear that screening high-risk individuals using low-dose computed tomography scans offers a safe and effective way to shift diagnosis to earlier stages and reduce mortality from lung cancer[5,6]. Complementary approaches, such as incidental pulmonary nodule identification, management protocols and rapid referral pathways from primary to secondary care, are also important to improve early detection[7,8]. Improvements to lung cancer care pathways are needed to ensure all people have access to multidisciplinary care that encompasses specialist diagnosis, personalised treatments, and palliative and survivorship care[7,8]. Finally, targeted efforts are required to reduce geographical and socioeconomic disparities in access and outcomes[9,10]. Making these changes can deliver benefits beyond lung cancer. Targeted screening programmes offer the opportunity for early detection of other non-communicable diseases (NCDs), such as chronic obstructive pulmonary disease and some forms of heart disease[11-13]. Tackling lung cancer can help countries progress towards reducing the overall burden of NCDs on their societies and contribute to greater health system sustainability. With the implementation of Europe’s Beating Cancer Plan and as we look to post-COVID recovery, we have the opportunity to put in place what is needed to improve outcomes for people with lung cancer and reduce the burden the condition poses on our societies. Lung cancer has, for too long, been denied due attention as a public health priority. The time to act is now.
  10 in total

1.  Frequency and distribution of incidental findings deemed appropriate for S modifier designation on low-dose CT in a lung cancer screening program.

Authors:  Michael J Reiter; Allison Nemesure; Ezemonye Madu; Lisa Reagan; April Plank
Journal:  Lung Cancer       Date:  2018-03-20       Impact factor: 5.705

2.  Reduced lung-cancer mortality with low-dose computed tomographic screening.

Authors:  Denise R Aberle; Amanda M Adams; Christine D Berg; William C Black; Jonathan D Clapp; Richard M Fagerstrom; Ilana F Gareen; Constantine Gatsonis; Pamela M Marcus; JoRean D Sicks
Journal:  N Engl J Med       Date:  2011-06-29       Impact factor: 91.245

3.  Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial.

Authors:  Harry J de Koning; Carlijn M van der Aalst; Pim A de Jong; Ernst T Scholten; Kristiaan Nackaerts; Marjolein A Heuvelmans; Jan-Willem J Lammers; Carla Weenink; Uraujh Yousaf-Khan; Nanda Horeweg; Susan van 't Westeinde; Mathias Prokop; Willem P Mali; Firdaus A A Mohamed Hoesein; Peter M A van Ooijen; Joachim G J V Aerts; Michael A den Bakker; Erik Thunnissen; Johny Verschakelen; Rozemarijn Vliegenthart; Joan E Walter; Kevin Ten Haaf; Harry J M Groen; Matthijs Oudkerk
Journal:  N Engl J Med       Date:  2020-01-29       Impact factor: 91.245

4.  Lifetime Smoking History and Risk of Lung Cancer: Results From the Framingham Heart Study.

Authors:  Hilary A Tindle; Meredith Stevenson Duncan; Robert A Greevy; Ramachandran S Vasan; Suman Kundu; Pierre P Massion; Matthew S Freiberg
Journal:  J Natl Cancer Inst       Date:  2018-11-01       Impact factor: 13.506

Review 5.  Global trends of lung cancer mortality and smoking prevalence.

Authors:  Farhad Islami; Lindsey A Torre; Ahmedin Jemal
Journal:  Transl Lung Cancer Res       Date:  2015-08

Review 6.  Contemporary issues in the implementation of lung cancer screening.

Authors:  Stephen Lam; Martin Tammemagi
Journal:  Eur Respir Rev       Date:  2021-07-20

7.  Barriers to uptake among high-risk individuals declining participation in lung cancer screening: a mixed methods analysis of the UK Lung Cancer Screening (UKLS) trial.

Authors:  Noor Ali; Kate J Lifford; Ben Carter; Fiona McRonald; Ghasem Yadegarfar; David R Baldwin; David Weller; David M Hansell; Stephen W Duffy; John K Field; Kate Brain
Journal:  BMJ Open       Date:  2015-07-14       Impact factor: 2.692

8.  Prevalence, Symptom Burden, and Underdiagnosis of Chronic Obstructive Pulmonary Disease in a Lung Cancer Screening Cohort.

Authors:  Mamta Ruparel; Samantha L Quaife; Jennifer L Dickson; Carolyn Horst; Sophie Tisi; Helen Hall; Magali N Taylor; Asia Ahmed; Penny J Shaw; Stephen Burke; May-Jan Soo; Arjun Nair; Anand Devaraj; Karen Sennett; John R Hurst; Stephen W Duffy; Neal Navani; Angshu Bhowmik; David R Baldwin; Sam M Janes
Journal:  Ann Am Thorac Soc       Date:  2020-07

9.  Evaluation of cardiovascular risk in a lung cancer screening cohort.

Authors:  Mamta Ruparel; Samantha L Quaife; Jennifer L Dickson; Carolyn Horst; Stephen Burke; Magali Taylor; Asia Ahmed; Penny Shaw; May-Jan Soo; Arjun Nair; Anand Devaraj; Emma Louise O'Dowd; Angshu Bhowmik; Neal Navani; Karen Sennett; Stephen W Duffy; David R Baldwin; Reecha Sofat; Riyaz S Patel; Aroon Hingorani; Sam M Janes
Journal:  Thorax       Date:  2019-09-26       Impact factor: 9.102

10.  High-Ambient Air Pollution Exposure Among Never Smokers Versus Ever Smokers With Lung Cancer.

Authors:  Renelle Myers; Michael Brauer; Trevor Dummer; Sukhinder Atkar-Khattra; John Yee; Barbara Melosky; Cheryl Ho; Anna L McGuire; Sophie Sun; Kyle Grant; Alexander Lee; Martha Lee; Weiran Yuchi; Martin Tammemagi; Stephen Lam
Journal:  J Thorac Oncol       Date:  2021-07-10       Impact factor: 15.609

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.